BarentsKrans has advised Quadrum Capital on its investment in JASA Group
A team of BarentsKrans has advised investment company Quadrum Capital with its investment in JASA Group. JASA develops, assembles and produces packaging machines and complete weighing and packaging lines. The team is led by Eduard de Haan, who as CEO has already successfully worked together with a large part of the management. “We are very
BarentsKrans advised Benedictus Holding B.V. and T. Kuyvenhoven Holding B.V. on the sale of Liones Holding B.V.
BarentsKrans has advised Benedictus Holding B.V. and T. Kuyvenhoven Holding B.V. on the sale of Liones Holding B.V., a company that provides software for structured content authoring through its Dutch subsidiaries (among which Fonto Group B.V.), to SDL Holdings B.V., a (indirect) subsidiary of the British RWS Holdings. Through this sale, Liones Holding B.V. and
BarentsKrans has advised Axion BioSystems on its acquisition of CytoSMART
Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the Netherlands-based CytoSMART Technologies—an innovator in kinetic live-cell imaging analysis. The collaboration positions Axion for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. “Since Axion BioSystems’ inception, our focus has
BarentsKrans has advised on the participation of APB and Shell in enie.nl
ABP contributes to the financing of the energy transition in the Netherlands through the ABP Netherlands Energy transition fund (ANET), among other vehicles. For ABP, it is clear that enie.nl will play a key role in the further necessary growth of solar energy in the Netherlands and abroad. Solar panels currently make up only 9.5%
BarentsKrans advices sell-side in acquisition Eekels Pompen by Boels
BarentsKrans advised sell-side regarding the sale of Eekels Pompen B.V. and Eekels Materieelbeheer B.V. (in short: Eekels Pompen) to Boels-Gosink B.V., a subsidiary within the Boels group. Eekels Pompen has been offering specialised solutions in the area of pump installations for over a hundred years and contributes to national and international (pump) projects with more
BarentsKrans assisted VanderSat Holding on the sale of VanderSat to Planet Labs
BarentsKrans advised VanderSat Holding on the sale of specialized Dutch software developer VanderSat to Planet Labs, an American satellite company based in San Francisco. The transaction closed on 13 December 2021. Through this sale, VanderSat will be able to broaden its network and possibilities to use its science and technology on an even larger scale.
BarentsKrans advises the shareholders of Just-BI on the sale of their shares to EPAM Systems
BarentsKrans has advised the shareholders of Just-BI on the sale of their shares to EPAM Systems Just-BI is involved in end-to-end design and implementation projects in a range of major national and international companies. Just-BI offers a core of senior consultants who support your business every step of the way. Rad Parvn, Just-BI CEO says
BarentsKrans advises Mourik on the acquisition of 50% of the shares in Van Spijker Infrabouw B.V.
BarentsKrans has advised Mourik on the acquisition of 50% of the shares in Van Spijker Infrabouw B.V. located in Meppel. Kees Jan Mourik, CEO of Mourik, states that “Van Spijker has the same predilection as Mourik for innovation to carry out projects much more smarter and cleaner. Mourik and Van Spijker have a mutual focus
BarentsKrans advises Horticoop on the acquisition of the shares in SmartCoat B.V.
BarentsKrans has advised Horticoop on the acquisition of the shares in SmartCoat B.V. from Finoxa. Horticoop already held 80% of the shares and became the sole shareholder of Smartcoat at the end of 2020 as a result of this transaction. SmartCoat is with her brands Redusysems and Sudlac active in more than 50 countries and
BarentsKrans advises Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics
BarentsKrans has advised Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics. Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS (Central Nervous System) disorders. “At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our